EP3154522A1 - Agomelatine in solution adsorbates and compositions - Google Patents

Agomelatine in solution adsorbates and compositions

Info

Publication number
EP3154522A1
EP3154522A1 EP15731717.3A EP15731717A EP3154522A1 EP 3154522 A1 EP3154522 A1 EP 3154522A1 EP 15731717 A EP15731717 A EP 15731717A EP 3154522 A1 EP3154522 A1 EP 3154522A1
Authority
EP
European Patent Office
Prior art keywords
agomelatine
adsorbate
peg
composition according
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15731717.3A
Other languages
German (de)
French (fr)
Inventor
Giorgio Bertolini
Cinzia BIAGGI
Ilaria FERRANDO
Dieter Ruchatz
Hendrik Schlehahn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alfred E Tiefenbacher GmbH and Co KG
Laboratorio Chimico Internazionale SpA
Original Assignee
Alfred E Tiefenbacher GmbH and Co KG
Laboratorio Chimico Internazionale SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfred E Tiefenbacher GmbH and Co KG, Laboratorio Chimico Internazionale SpA filed Critical Alfred E Tiefenbacher GmbH and Co KG
Publication of EP3154522A1 publication Critical patent/EP3154522A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Definitions

  • the present invention relates to a new agomelatine composition, particularly agomelatine in solution which is adsorbed on an inert carrier or directly formulated.
  • Another subject-matter of the invention is a solid form made of an agomelatine in solution adsorbate and a process for the preparation of said solid form as well as the use of the adsorbate and of the composition in therapy, and pharmaceutical compositions comprising the same.
  • Agomelatine is an antidepressant drug having the following formula (I)
  • Agomelatine is currently commercially available only in solid form.
  • the solubility does not represent a limiting factor for bioavailability.
  • An object of the invention is to provide a new solid form of agomelatine in solution which can be absorbed in an effective and very fast way.
  • Another object of the invention is to provide a new solid form of agomelatine in solution, in which said agomelatine is dissolved in a solvent and adsorbed on an inert carrier.
  • Another object of the invention is to provide a process for the preparation of said new solid form of agomelatine.
  • Another object of the invention is to provide a new solid form of agomelatine which can be easily processed and formulated into pharmaceutical compositions.
  • a further object of the invention is to provide pharmaceutical compositions comprising the adsorbates of agomelatine in solution.
  • Another object of the invention is to provide pharmaceutical compositions comprising the agomelatine in solution.
  • Figure 1 shows the dissolution profiles of presently marketed agomelatine and of representative compositions according to the invention.
  • an object of the invention is a new solid form which consists of an adsorbate of agomelatine in solution on one or more pharmaceutically acceptable inert solid carriers, particularly an adsorbate of agomelatine, characterized in that it is agomelatine in solution in a pharmaceutically acceptable solvent which is adsorbed on at least one pharmaceutically acceptable inert solid carrier.
  • solid form means a pharmaceutical formulation, in the specific case of agomelatine, which occurs as a stable solid which is suitable either to be used as such or to be formulated into a pharmaceutical composition.
  • the term “adsorbate(s)” refers to solid mixtures in which a solution of agomelatine in a pharmaceutically acceptable solvent is supported on one or more pharmaceutically acceptable inert solid carriers.
  • the term “agomelatine in solution” is meant to refer to a solution of agomelatine in one or more pharmaceutically acceptable solvents.
  • Suitable solvents according to the invention are, for example, polyethylene glycols (PEGs); polysorbates, for example polysorbate 20, polysorbate 40, polysorbate 60 and polysorbate 80; triglycerides, for example the triglycerides sold under the trade name Miglyol ® or 1,2,3-triacetoxypropane (Triacetin); coconut oil, castor oil; cotton seed oil; corn seed oil; etc., and mixtures thereof.
  • PEGs polyethylene glycols
  • polysorbates for example polysorbate 20, polysorbate 40, polysorbate 60 and polysorbate 80
  • triglycerides for example the triglycerides sold under the trade name Miglyol ® or 1,2,3-triacetoxypropane (Triacetin)
  • Miglyol ® 1,2,3-triacetoxypropane
  • Triacetin 1,2,3-triacetoxypropane
  • suitable solvents according to the invention are selected from Transcutol (diethyleneglycol monoethyl ether), Labrasol (caprylocaproyl macrogol-8 glycerides), Kolliphor EL (Polyoxyl castor oil), Kollisolv P 124 (poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol)) and mixture therof.
  • the above solvents may be mixed together or with other solvents, such as for instance, lower alcohols, such as methanol or ethanol.
  • One of the preferred solvent according to the invention is PEG, advantageously a PEG having a molecular weight from 200 to 800, for example of 200, 400, 600 and 800.
  • the solvent is PEG 400.
  • Transcutol diethyleneglycol monoethyl ether
  • Labrasol caprylocaproyl macrogol-8 glycerides
  • Kolliphor EL Polyoxyl castor oil
  • Kollisolv P 124 poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) or Poloxamer 124.
  • an "inert solid carrier” is meant to refer to any pharmaceutically acceptable “filler” agent which is used in the pharmaceutical arts.
  • suitable inert solid carriers include, for example, silica, advantageously colloidal silica, saccharides, polysaccharides such as cyclodextrins, starches, maltodextrins, cellulose and derivatives thereof, lactose, mannitol; salts or minerals such as magnesium and aluminum silicates, kaolin, talc, calcium phosphates; certain solid polyalcohols such as sorbitol; magnesium salts of fatty acids; zeolites; and pharmaceutically acceptable water-soluble polymers, such as solid high molecular weight PEGs (polyethylene glycols), PVP (polyvinylpyrrolidone) and the like.
  • PEGs polyethylene glycols
  • PVP polyvinylpyrrolidone
  • the inert solid carriers are selected from colloidal silicas, advantageously anhydrous and amorphous colloidal silicas such as the silica currently marketed under the trade name
  • the inert solid carriers are selected from cellulose and derivatives thereof, such as microcrystalline cellulose, carboxymethyl cellulose and hydroxypropyl methylcellulose.
  • the inert solid carriers are selected from cyclodextrins, for example beta- or gamma-cyclodextrin, starch, lactose and maltodextrins.
  • the adsorbates of the invention may include agomelatine solutions and one or more pharmaceutically acceptable inert solid carriers.
  • Representative solid carrier which can be mixed up to are preferably selected from colloidal silica, microcrystalline cellulose, dicalcium phosphate anhydrous magnesium aluminum silicate and magnesium stearate.
  • the formation of the solid is carried out by mixing the agomelatine solution with the carrier, or carriers, at room temperature.
  • an object of the invention is a new process for the preparation of adsorbates of agomelatine solutions, which comprises:
  • step (a) b. adding one or more pharmaceutically acceptable inert solid carriers to the solution obtained in step (a); c. stirring the thus obtained suspension until a powder is obtained.
  • the invention relates to a process for the preparation of adsorbates of agomelatine solutions, which consists of steps (a) to (c) above.
  • step (a) The entire procedure can be carried out at room temperature. However, if necessary, during step (a), it is possible to heat or sonicate in order to promote the dissolution of agomelatine. There is no need to add acids or any other liquid or solid ingredient to achieve the solution of step (a).
  • step (c) The mixture obtained in step (c) is initially a fine suspension which is then properly stirred in order to transform it into a powder.
  • the powder obtained by the process of the invention can be sieved in order to obtain a more homogeneous particle size.
  • the formation of the agomelatine adsorbate occurs without the need of any intervention, i.e. no particular technique must be carried out, such as for instance, freeze-drying or granulation.
  • adsorbates of the invention which are advantageously but not necessarily prepared according to the process described herein, occur as a powder which is perfectly stable and processable.
  • agomelatine stays in solution in the adsorbates and in the compositions and does not convert into any crystalline form. This is an excellent result, as it does not tend to crystallize over the time. Indeed, the dissolved and absorbed agomelatine does not precipitate, neither into a crystalline, amorphous, or any other solid form. Agomelatine remains completely in solution after absorption onto the solid carrier (sponge effect).
  • the agomelatine/carrier/solvent ratios vary depending on the carriers and solvents selected for use.
  • the ratios may be in the range from 1/10/10 to 1/1/1, preferably from 1/8/8 to 1/3/5, for example 1/2,5/4, 1/2,3/3,75, 1/2/3,5, etc.
  • the weight amount of agomelatine in the adsorbate will depend on the above ratio.
  • the weight amount of agomelatine in the adsorbate could vary from 5 to 40%, preferably from 10 to 30%, for example 15-25%.
  • Adsorbates in which PEG 400 is used as the solvent and a colloidal silica is used as the carrier are preferred according to the invention, advantageously in the ratios indicated above.
  • adsobates wherein Transcutol (diethyleneglycol monoethyl ether) is used as a solvent and the carrier is a mixture of carriers, for instance such as those selected from colloidal silica, microcrystalline cellulose, dicalcium phosphate anhydrous magnesium aluminum silicate and magnesium stearate.
  • Transcutol diethyleneglycol monoethyl ether
  • the carrier is a mixture of carriers, for instance such as those selected from colloidal silica, microcrystalline cellulose, dicalcium phosphate anhydrous magnesium aluminum silicate and magnesium stearate.
  • the adsorbates of the invention allow to obtain a powder of agomelatine in solution which is perfectly stable and processable and which can be used, for example, for the preparation of solid pharmaceutical compositions, such as tablets or capsules, but also suspensions and suppositories as well as patches for buccal delivery (“buccal patches”) or even patches for transdermal delivery (“transdermal patches”), preferably with the addition of one or more conventional pharmaceutically acceptable excipients or carriers.
  • said adsorbates are only made of agomelatine, one or more solvents and one or more inert carriers as defined above, i.e. they are prepared in the absence of any further substance, such as for instance acidic and or alkalizing agents.
  • agomelatine existing in the new form of the invention is already in solution, it has the advantage of being absorbed faster because it does not require to pass from the solid state to a state of solution in a body fluid, which is an important and significant technical advancement.
  • agomelatine stays in solution in the adsorbates of the invention.
  • the compositions prepared with the adsorbates of the invention does not show any crystalline form by XRD, even after accelerated condition assays (40°C/75 RH, in HDPE containers).
  • compositions comprising the adsorbates of the invention are a further subject-matter of the invention, especially in the form of tablets or capsules as well as the use of the adsorbates and of the pharmaceutical compositions comprising them in therapy, in particular for the treatment of depression.
  • the invention also encompasses a method for treating depression, which comprises administering an effective amount of an adsorbate of the invention, advantageously in the form of a pharmaceutical composition, preferably as a tablet or a capsule, optionally in combination with other active ingredients and with conventional excipients and carriers, to a subject in need thereof.
  • compositions of the invention are particularly suitable for oral administration although, as already mentioned, other forms of administration may be used as well.
  • compositions can be in the form of tablets, capsules or granules, and they are prepared according to conventional methods with the use of pharmaceutically acceptable excipients such as binding agents, filler agents, lubricants, disintegrants, wetting agents, flavouring agents, etc.
  • the tablets can also be coated by methods well known in the art.
  • Capsules and tablets are preferred pharmaceutical compositions and the skilled in the art is perfectly able to select conventional carriers and excipients which can be included in the compositions of the invention.
  • compositions and adsorbates of the invention are also particularly suitable for buccal administration, by which agomelatine can be rapidly absorbed through the mucosa of the mouth because it is already in solution.
  • the adsorbates of the invention are suitable for the preparation of transdermal and transmucosal compositions in virtue of the immediate availability of the active ingredient in solution.
  • each dosage unit according to the invention comprises an amount of agomelatine from 1 to 100 mg, for example from 5 to 80 mg, advantageously from 30 to 50 mg, for example of about 25 mg and, if desired or necessary, conventional excipients and additives well known to one skilled in the art.
  • the adsorbate can be formulated in combination with other active ingredients.
  • the adsorbate of agomelatine solution is formulated as the sole active ingredient.
  • the invention allows to formulate agomelatine in a simple and industrially convenient manner, obtaining compositions from which agomelatine is rapidly absorbed by the body.
  • the adsorbates of the invention represent a new, original alternative to the known compositions of agomelatine.
  • agomelatine An unpredictably very rapid release of agomelatine was observed with respect of the conventional tablets, which are however already quickly dissolved.
  • agomelatine in Valdoxan tablets shows an immediate drug release profile, this means that 75% of the agomelatine is dissolved within 45 minutes.
  • agomelatine adsorbates compositions show a dramatic improved dissolution rate compared to agomelatine Valdoxan reference.
  • Figure 1 shows the dissolution rates of Valdoxan, and of compositions comprising agomelatine adsorbates manufactured according to the invention.
  • the process of the invention here especially directed to obtaining adsorbates of agomelatine in solution, can be applied to any other drug which is dissolved in a suitable solvent or mixture of solvents, thus providing new solid forms consisting of adsorbates of drugs in solution.
  • adsorbates as well as the process for their preparation, the pharmaceutical compositions containing them and the use thereof in therapy, represent a further aspect of the invention.
  • agomelatine 1 g was dissolved in 7.52 g of PEG 400 at room temperature under magnetic stirring. 3.76 g of colloidal silica (Aerosil ® 200) was then added, and the mixture was kept under stirring until a fine powder was formed. The powder was then sieved through a steel sieve of 500 micron to obtain the title adsorbate.
  • the weight content of agomelatine in the adsorbate is approx. 8.4%.
  • Example 1 is repeated using 1 g of agomelatine, 7.52 g of PEG 400 and 7.52 g of g of colloidal silica (Aerosil ® 200).
  • the weight content of agomelatine in the adsorbate is approx. 6.2%.
  • Example 1 is repeated using 1 g of agomelatine, 3.76 g of PEG 400 and 2.3 g of colloidal silica (Aerosil ® 200).
  • the weight content of agomelatine in the adsorbate is about 12.8%.
  • Example 1 is repeated using 25 mg of agomelatine, 125 mg of diethyleneglycol monoethyl ether (Transcutol HP), 50 mg od colloidal silica (Aerosil ® 200), 100 mg of microcrystalline cellulose, 100 mg dicalcium phosphate anhydrous and 6 mg of magnesium stearate.
  • Lubricated blend was filled in Size "1" white opaque/opaque empty hard gelatin capsules by using Pam-manual capsules filling machine.
  • Average Weight of filled capsule (mg) 516.5 519.2 515.8
  • Example 7 The compositions of Example 7 were also compressed to obtain tablets.
  • Lubricated material was compressed into tablets using 9.0 mm

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a new agomelatine composition, particularly agomelatine in solution which isadsorbed on an inert carrier or directly formulated. Another subject-matter of the invention is a solid form made of an agomelatine in solution adsorbate and a process for the preparation of said solid form as well as the use of the adsorbate and of the composition in therapy, and pharmaceutical compositions comprising the same.

Description

"Agomelatine in solution adsorbates and compositions
Summary of the Invention
The present invention relates to a new agomelatine composition, particularly agomelatine in solution which is adsorbed on an inert carrier or directly formulated. Another subject-matter of the invention is a solid form made of an agomelatine in solution adsorbate and a process for the preparation of said solid form as well as the use of the adsorbate and of the composition in therapy, and pharmaceutical compositions comprising the same.
Technical Background
Agomelatine is an antidepressant drug having the following formula (I)
In the pharmaceutical field, research is constantly underway to find new formulations for active ingredients which are more effective and/or more rapid and reliable to be adsorbed.
Agomelatine is currently commercially available only in solid form.
It is well known that the bioavailability of solid pharmaceutical compositions administered by the oral or rectal route is significantly influenced by the dissolution rate of the active ingredient. If the dissolution rate of a drug in the intestinal lumen is low compared to the absorption rate, the drug remains partially undissolved and, as such, it is cleared.
Conversely, if the drug is administered in the form of a solution, the solubility does not represent a limiting factor for bioavailability.
Objects of the Invention
An object of the invention is to provide a new solid form of agomelatine in solution which can be absorbed in an effective and very fast way.
Another object of the invention is to provide a new solid form of agomelatine in solution, in which said agomelatine is dissolved in a solvent and adsorbed on an inert carrier.
Another object of the invention is to provide a process for the preparation of said new solid form of agomelatine.
Another object of the invention is to provide a new solid form of agomelatine which can be easily processed and formulated into pharmaceutical compositions.
A further object of the invention is to provide pharmaceutical compositions comprising the adsorbates of agomelatine in solution.
Finally, another object of the invention is to provide pharmaceutical compositions comprising the agomelatine in solution.
Brief description of the drawing
Figure 1 shows the dissolution profiles of presently marketed agomelatine and of representative compositions according to the invention.
Description of the Invention
Now, it has been found that it is possible to prepare a solid form of agomelatine in solution. Particularly, it has been found that, when a solution of agomelatine in a suitable solvent is adsorbed onto an inert solid, it is easy to obtain solids which are stable and easily processable from the industrial point of view.
Thus, according to one of its aspects, an object of the invention is a new solid form which consists of an adsorbate of agomelatine in solution on one or more pharmaceutically acceptable inert solid carriers, particularly an adsorbate of agomelatine, characterized in that it is agomelatine in solution in a pharmaceutically acceptable solvent which is adsorbed on at least one pharmaceutically acceptable inert solid carrier.
According to the present invention, the term "solid form" means a pharmaceutical formulation, in the specific case of agomelatine, which occurs as a stable solid which is suitable either to be used as such or to be formulated into a pharmaceutical composition.
Here, the term "adsorbate(s)" refers to solid mixtures in which a solution of agomelatine in a pharmaceutically acceptable solvent is supported on one or more pharmaceutically acceptable inert solid carriers. According to the present invention, the term "agomelatine in solution" is meant to refer to a solution of agomelatine in one or more pharmaceutically acceptable solvents. Suitable solvents according to the invention are, for example, polyethylene glycols (PEGs); polysorbates, for example polysorbate 20, polysorbate 40, polysorbate 60 and polysorbate 80; triglycerides, for example the triglycerides sold under the trade name Miglyol® or 1,2,3-triacetoxypropane (Triacetin); coconut oil, castor oil; cotton seed oil; corn seed oil; etc., and mixtures thereof.
Other suitable solvents according to the invention are selected from Transcutol (diethyleneglycol monoethyl ether), Labrasol (caprylocaproyl macrogol-8 glycerides), Kolliphor EL (Polyoxyl castor oil), Kollisolv P 124 (poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol)) and mixture therof.
Other solvents, which are able to dissolve agomelatine, may be used according to the invention.
If needed or desire, the above solvents may be mixed together or with other solvents, such as for instance, lower alcohols, such as methanol or ethanol.
One of the preferred solvent according to the invention is PEG, advantageously a PEG having a molecular weight from 200 to 800, for example of 200, 400, 600 and 800. According to a preferred embodiment, the solvent is PEG 400.
Another preferred solvent is Transcutol (diethyleneglycol monoethyl ether), alone or in combination with other solvents such as, for instance, Labrasol (caprylocaproyl macrogol-8 glycerides), or Kolliphor EL (Polyoxyl castor oil) or Kollisolv P 124 (poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) or Poloxamer 124).
Here, an "inert solid carrier" is meant to refer to any pharmaceutically acceptable "filler" agent which is used in the pharmaceutical arts. Suitable inert solid carriers include, for example, silica, advantageously colloidal silica, saccharides, polysaccharides such as cyclodextrins, starches, maltodextrins, cellulose and derivatives thereof, lactose, mannitol; salts or minerals such as magnesium and aluminum silicates, kaolin, talc, calcium phosphates; certain solid polyalcohols such as sorbitol; magnesium salts of fatty acids; zeolites; and pharmaceutically acceptable water-soluble polymers, such as solid high molecular weight PEGs (polyethylene glycols), PVP (polyvinylpyrrolidone) and the like.
According to an advantageous embodiment of the invention, the inert solid carriers are selected from colloidal silicas, advantageously anhydrous and amorphous colloidal silicas such as the silica currently marketed under the trade name
"Aerosil ' particularly the silica defined as "Aerosil 200".
According to another advantageous embodiment of the invention, the inert solid carriers are selected from cellulose and derivatives thereof, such as microcrystalline cellulose, carboxymethyl cellulose and hydroxypropyl methylcellulose.
According to another advantageous embodiment of the invention, the inert solid carriers are selected from cyclodextrins, for example beta- or gamma-cyclodextrin, starch, lactose and maltodextrins.
The adsorbates of the invention may include agomelatine solutions and one or more pharmaceutically acceptable inert solid carriers.
Representative solid carrier which can be mixed up to are preferably selected from colloidal silica, microcrystalline cellulose, dicalcium phosphate anhydrous magnesium aluminum silicate and magnesium stearate.
Examples of representative adsorbates according to the invention are disclosed in the experimental section of this description.
In order to obtain a homogeneous dispersion of the agomelatine solution onto the inert carrier, it has been found that it is sufficient to mix a solution of agomelatine in a suitable pharmaceutically acceptable solvent with the carrier of choice, and keep the suspension under stirring until a powder is formed.
Preferably, the formation of the solid is carried out by mixing the agomelatine solution with the carrier, or carriers, at room temperature.
Thus, according to another of its aspects, an object of the invention is a new process for the preparation of adsorbates of agomelatine solutions, which comprises:
a. dissolving agomelatine in a pharmaceutically acceptable solvent or mixture of solvents;
b. adding one or more pharmaceutically acceptable inert solid carriers to the solution obtained in step (a); c. stirring the thus obtained suspension until a powder is obtained.
According to an embodiment, the invention relates to a process for the preparation of adsorbates of agomelatine solutions, which consists of steps (a) to (c) above.
The entire procedure can be carried out at room temperature. However, if necessary, during step (a), it is possible to heat or sonicate in order to promote the dissolution of agomelatine. There is no need to add acids or any other liquid or solid ingredient to achieve the solution of step (a).
The mixture obtained in step (c) is initially a fine suspension which is then properly stirred in order to transform it into a powder.
If desired or necessary, the powder obtained by the process of the invention can be sieved in order to obtain a more homogeneous particle size.
So, according to the invention, the formation of the agomelatine adsorbate occurs without the need of any intervention, i.e. no particular technique must be carried out, such as for instance, freeze-drying or granulation. This represent a great advantage and with respect to the prior art, the process being simple and cost-effective, which is extremely important especially from an industrial point of view.
The adsorbates of the invention, which are advantageously but not necessarily prepared according to the process described herein, occur as a powder which is perfectly stable and processable.
It was surprisingly noticed that agomelatine stays in solution in the adsorbates and in the compositions and does not convert into any crystalline form. This is an excellent result, as it does not tend to crystallize over the time. Indeed, the dissolved and absorbed agomelatine does not precipitate, neither into a crystalline, amorphous, or any other solid form. Agomelatine remains completely in solution after absorption onto the solid carrier (sponge effect).
The agomelatine/carrier/solvent ratios vary depending on the carriers and solvents selected for use.
For example, when PEG 400 is used as the solvent and a colloidal silica is used as the carrier, the ratios may be in the range from 1/10/10 to 1/1/1, preferably from 1/8/8 to 1/3/5, for example 1/2,5/4, 1/2,3/3,75, 1/2/3,5, etc.
The weight amount of agomelatine in the adsorbate will depend on the above ratio. For instance, the weight amount of agomelatine in the adsorbate could vary from 5 to 40%, preferably from 10 to 30%, for example 15-25%.
Adsorbates in which PEG 400 is used as the solvent and a colloidal silica is used as the carrier are preferred according to the invention, advantageously in the ratios indicated above.
Also preferred are adsobates wherein Transcutol (diethyleneglycol monoethyl ether) is used as a solvent and the carrier is a mixture of carriers, for instance such as those selected from colloidal silica, microcrystalline cellulose, dicalcium phosphate anhydrous magnesium aluminum silicate and magnesium stearate.
As already said, the adsorbates of the invention allow to obtain a powder of agomelatine in solution which is perfectly stable and processable and which can be used, for example, for the preparation of solid pharmaceutical compositions, such as tablets or capsules, but also suspensions and suppositories as well as patches for buccal delivery ("buccal patches") or even patches for transdermal delivery ("transdermal patches"), preferably with the addition of one or more conventional pharmaceutically acceptable excipients or carriers.
Preferably said adsorbates are only made of agomelatine, one or more solvents and one or more inert carriers as defined above, i.e. they are prepared in the absence of any further substance, such as for instance acidic and or alkalizing agents.
In contrast to the currently available solid or semi-solid formulations, since agomelatine existing in the new form of the invention is already in solution, it has the advantage of being absorbed faster because it does not require to pass from the solid state to a state of solution in a body fluid, which is an important and significant technical advancement.
As stated above, surprisingly, agomelatine stays in solution in the adsorbates of the invention. Indeed, the compositions prepared with the adsorbates of the invention does not show any crystalline form by XRD, even after accelerated condition assays (40°C/75 RH, in HDPE containers).
The pharmaceutical compositions comprising the adsorbates of the invention are a further subject-matter of the invention, especially in the form of tablets or capsules as well as the use of the adsorbates and of the pharmaceutical compositions comprising them in therapy, in particular for the treatment of depression.
The invention also encompasses a method for treating depression, which comprises administering an effective amount of an adsorbate of the invention, advantageously in the form of a pharmaceutical composition, preferably as a tablet or a capsule, optionally in combination with other active ingredients and with conventional excipients and carriers, to a subject in need thereof.
The pharmaceutical compositions of the invention are particularly suitable for oral administration although, as already mentioned, other forms of administration may be used as well.
For oral administration, said compositions can be in the form of tablets, capsules or granules, and they are prepared according to conventional methods with the use of pharmaceutically acceptable excipients such as binding agents, filler agents, lubricants, disintegrants, wetting agents, flavouring agents, etc. The tablets can also be coated by methods well known in the art. Capsules and tablets are preferred pharmaceutical compositions and the skilled in the art is perfectly able to select conventional carriers and excipients which can be included in the compositions of the invention.
The compositions and adsorbates of the invention are also particularly suitable for buccal administration, by which agomelatine can be rapidly absorbed through the mucosa of the mouth because it is already in solution.
According to another advantageous embodiment of the invention, the adsorbates of the invention are suitable for the preparation of transdermal and transmucosal compositions in virtue of the immediate availability of the active ingredient in solution.
The compositions of the invention are advantageously in the form of dosage units. Preferably, each dosage unit according to the invention comprises an amount of agomelatine from 1 to 100 mg, for example from 5 to 80 mg, advantageously from 30 to 50 mg, for example of about 25 mg and, if desired or necessary, conventional excipients and additives well known to one skilled in the art.
Obviously, other dosages can be envisaged depending on the diseases and conditions of the subject to be treated. Thanks to the stability of the adsorbates of the invention in the compositions according to the invention, the adsorbate can be formulated in combination with other active ingredients. According to a preferred embodiment, in the compositions according to the invention, the adsorbate of agomelatine solution is formulated as the sole active ingredient.
Thus, it is easily understood that the invention allows to formulate agomelatine in a simple and industrially convenient manner, obtaining compositions from which agomelatine is rapidly absorbed by the body.
Accordingly, the adsorbates of the invention represent a new, original alternative to the known compositions of agomelatine.
Dissolution tests carried out on tablets and capsules comprising the new solid form of the invention have shown that the adsorbates of the invention are more readily available in the test liquid than the known compositions of agomelatine.
Indeed, different experiments have been performed with capsules and tablets comprising agomelatine adsorbates, as such or in admixture with further inert carriers and excipients, to compare their dissolution trend with Valdoxan® tablets
(agomelatine currently on the market).
An unpredictably very rapid release of agomelatine was observed with respect of the conventional tablets, which are however already quickly dissolved.
Indeed, agomelatine in Valdoxan tablets shows an immediate drug release profile, this means that 75% of the agomelatine is dissolved within 45 minutes.
Representative agomelatine adsorbates compositions show a dramatic improved dissolution rate compared to agomelatine Valdoxan reference.
Figure 1 shows the dissolution rates of Valdoxan, and of compositions comprising agomelatine adsorbates manufactured according to the invention.
Obviously, the process of the invention, here especially directed to obtaining adsorbates of agomelatine in solution, can be applied to any other drug which is dissolved in a suitable solvent or mixture of solvents, thus providing new solid forms consisting of adsorbates of drugs in solution. Such adsorbates, as well as the process for their preparation, the pharmaceutical compositions containing them and the use thereof in therapy, represent a further aspect of the invention. Experimental Section
Example 1
Preparation of an adsorbate of a solution of agomelatine in PEG 400 with colloidal silica
1 g of agomelatine was dissolved in 7.52 g of PEG 400 at room temperature under magnetic stirring. 3.76 g of colloidal silica (Aerosil®200) was then added, and the mixture was kept under stirring until a fine powder was formed. The powder was then sieved through a steel sieve of 500 micron to obtain the title adsorbate. The weight content of agomelatine in the adsorbate is approx. 8.4%.
Example 2
Preparation of an adsorbate of a solution of agomelatine in PEG 400 with colloidal silica
Example 1 is repeated using 1 g of agomelatine, 7.52 g of PEG 400 and 7.52 g of g of colloidal silica (Aerosil®200). The weight content of agomelatine in the adsorbate is approx. 6.2%.
Example 3
Preparation of an adsorbate of a solution of agomelatine in PEG 400 with colloidal silica
Example 1 is repeated using 1 g of agomelatine, 3.76 g of PEG 400 and 2.3 g of colloidal silica (Aerosil®200). The weight content of agomelatine in the adsorbate is about 12.8%.
Example 4
Preparation of an adsorbate of a solution of agomelatine in Transcutol with a mixture of carriers
Example 1 is repeated using 25 mg of agomelatine, 125 mg of diethyleneglycol monoethyl ether (Transcutol HP), 50 mg od colloidal silica (Aerosil®200), 100 mg of microcrystalline cellulose, 100 mg dicalcium phosphate anhydrous and 6 mg of magnesium stearate.
An X-ray analysis of the adsorbates of Examples 1 to 4 did not show the presence of crystalline forms.
Example 5 Preparation of agomelatine adsorbate capsules
Agomelatine adsorbate was passed through #20 mesh.
Cellulose, microcrystalline, Crospovidone, Silica, colloidal, Anhydrous and Magnesium Stearate were sifted through #35 mesh.
- Sifted materials were mixed in polybag for around 5 minutes.
Lubricated blend was filled in Size "1" white opaque/opaque empty hard gelatin capsules by using Pam-manual capsules filling machine.
Prepared as disclosed in Example 1
Physical Parameters (Filled Capsule)
Average Weight of filled capsule (mg) 408.4 564.4
Average Net content (mg) 299.9 453.2
* Assuming weight of filled capsule is 104 mg.
Example 6
Comparative Dissolution profile in Acetate Buffer Solution pH 4.5, 1000 ml, 75 rpm, paddle
Dissolution minutes
Example 7
Preparation of agomelatine adsorbate capsules
Prepared as disclosed in in Example 4
Neusilin UFL2
Magnesium Stearate 6.100 6.100 6.100
Weight of Adsorbate 413.100 413.100 413.100
Encapsulation:
Empty Hard Gelatin Capsule Shells (Size
- Oel) (Pink/Opaque white) (Ref. No. : 104.000 104.000 104.000 0565/2012)
Weight of filled capsules 517.100 517.100 517.100
Physical Parameters (Filled Capsule)
Average Weight of filled capsule (mg) 516.5 519.2 515.8
Average Net content (mg) 414.5 414.9 411.1
* Assuming weight of filled capsule is 104 mg.
Example 8
Comparative Dissolution profile in Acetate Buffer Solution pH 4.5. 1000 ml. 75 rpm. paddle
Examp e 9
Preparation of agomelatine adsorbate tablets
The compositions of Example 7 were also compressed to obtain tablets.
Agomelatine adsorbate was passed through #20 mesh.
Other excipients were passed through #35 mesh.
Sifted materials were mixed in polybag for around 5 minutes.
Lubricated material was compressed into tablets using 9.0 mm
concave punches.

Claims

A pharmaceutical composition comprising an agomelatine adsorbate, characterized in that it is agomelatine in solution in a pharmaceutically acceptable solvent, adsorbed on at least one pharmaceutically acceptable inert solid carrier.
The composition according to claim 1, characterized in that it is a capsule.
The composition according to claim 1 or 2, characterized in that said at least one carrier is selected from silica, colloidal silica, saccharides, polysaccharides, magnesium and aluminium silicates, kaolin, talc, calcium phosphates, solid polyalcohols and magnesium salts of fatty acids, zeolites; and solid water-soluble polymers such as PEG and PVP, and the like.
The composition according to claim 1 or 2, characterized in that said at least one carrier is selected from silica, cyclodextrins, starches, maltodextrins, cellulose and derivatives thereof, lactose and mannitol.
The composition according to claim 1 or 2, characterized in that said at least one carrier is silicon dioxide (silica) or colloidal silica.
The composition according to any one of claims 1 to 5, characterized in that said pharmaceutically acceptable solvent is selected from polyethylene glycols (PEG), polysorbates, triglycerides, coconut oil, castor oil, cottonseed oil, corn oil, Transcutol (diethyleneglycol monoethyl ether), Labrasol (caprylocaproyl macrogol-8 glycerides), Kolliphor EL (Polyoxyl castor oil), Kollisolv P 124 (poly(ethylene glycol)-block-poly(propylene glycol)-block- poly(ethylene glycol), Poloxamer 124) and mixtures thereof.
The composition according to claim 6, characterized in that said solvent is a PEG.
The composition according to claim 7, characterized in that said PEG has a molecular weight comprised between 200 and 800.
The composition according to claim 8, characterized in that said PEG is PEG 400.
The composition according to any one of claims 1 to 9, characterized in that the agomelatine/solvent/solid carrier ratio is about 1/10/10 to 1/1/1 by weight. The composition according to claim 10, characterized in that said ratio is preferably between about 1/8/8 and 1/3/5.
The pharmaceutical composition according to any one of claims 1 to 11 which further comprises at least one pharmaceutically acceptable excipient or carrier.
An agomelatine adsorbate, characterized in that it is agomelatine in solution in a pharmaceutically acceptable solvent adsorbed on at least one pharmaceutically acceptable inert solid carrier, characterized in that agomelatine the weight amount of agomelatine in said adsorbate is 5 to 40%. An agomelatine adsorbate, characterized in that it is agomelatine in solution in a pharmaceutically acceptable solvent adsorbed on at least one pharmaceutically acceptable inert solid carrier, further characterized in that said pharmaceutically acceptable solvent is selected from polyethylene glycols (PEG), polysorbates, triglycerides, coconut oil, castor oil, cottonseed oil, corn oil, Transcutol (diethyleneglycol monoethyl ether), Labrasol (caprylocaproyl macrogol-8 glycerides), Kolliphor EL (Polyoxyl castor oil), Kollisolv P 124 (poly(ethylene glycol)-block-poly(propylene glycol)-block- poly(ethylene glycol), Poloxamer 124) and mixtures thereof.
The adsorbate according to claims 13 or 14, characterized in that said solvent is a PEG.
The adsorbate according to claim 15, characterized in that said PEG has a molecular weight comprised between 200 and 800.
The adsorbate according to claim 16, characterized in that said PEG is PEG 400.
The composition according to any one of claims 1 to 12 for use in therapy. The composition according to any one of claims 1 to 12, for use in the treatment of depression.
The adsorbate according to any one of claims 13 to 17 for use in therapy. The adsorbate according to any one of claims 13 to 17, for use in the treatment of depression.
A process for preparing adsorbates of agomelatine solutions comprising: a. dissolving agomelatine in a pharmaceutically acceptable solvent or mixture of solvents;
b. adding one or more inert solid carriers to the solution obtained in step (a); c. stirring the thus obtained suspension until obtaining a powder.
EP15731717.3A 2014-06-10 2015-06-10 Agomelatine in solution adsorbates and compositions Withdrawn EP3154522A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI20141057 2014-06-10
PCT/IB2015/054374 WO2015189778A1 (en) 2014-06-10 2015-06-10 Agomelatine in solution adsorbates and compositions

Publications (1)

Publication Number Publication Date
EP3154522A1 true EP3154522A1 (en) 2017-04-19

Family

ID=51230040

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15731717.3A Withdrawn EP3154522A1 (en) 2014-06-10 2015-06-10 Agomelatine in solution adsorbates and compositions

Country Status (2)

Country Link
EP (1) EP3154522A1 (en)
WO (1) WO2015189778A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017059877A1 (en) * 2015-10-07 2017-04-13 Rontis Hellas S.A. Pharmaceutical composition containing agomelatine and process for the preparation thereof
WO2017206096A1 (en) * 2016-06-01 2017-12-07 浙江华海药业股份有限公司 Agomelatine soft capsule preparation
CN108785373B (en) * 2018-07-04 2022-08-09 河南济世药业有限公司 Rabdosia rubescens superfine powder and preparation method thereof
EP4076381A1 (en) * 2019-12-20 2022-10-26 LTS Lohmann Therapie-Systeme AG Transmucosal therapeutic system containing agomelatine
CN115919809A (en) * 2019-12-20 2023-04-07 罗曼治疗系统股份公司 Transmucosal therapeutic system containing agomelatine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101781226B (en) * 2009-12-23 2012-03-28 天津泰普药品科技发展有限公司 Agomelatine and medicine composition thereof
CN102106807B (en) * 2009-12-29 2013-03-27 上海中西制药有限公司 Method for preparing solid preparation and solid preparation
WO2012093402A1 (en) * 2011-01-04 2012-07-12 Symed Labs Limited Processes for the preparation of n-[2-(7-methoxy-1-naphthyl)ethyl]acetamide
WO2013063263A1 (en) * 2011-10-25 2013-05-02 Lycus Llc Pharmaceutical compositions for treating pain

Also Published As

Publication number Publication date
WO2015189778A1 (en) 2015-12-17

Similar Documents

Publication Publication Date Title
JP5714492B2 (en) Granules, methods for their preparation, and pharmaceuticals containing them
CN103550165B (en) A kind of pharmaceutical composition and preparation method thereof containing razaxaban
WO2015189778A1 (en) Agomelatine in solution adsorbates and compositions
KR102308973B1 (en) Improved pharmaceutical compositions of pimobendan
WO2015152433A1 (en) Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
JP2010150289A (en) Composition comprising drospirenone molecularly dispersed
JP6426293B2 (en) Dutasteride compositions in tablet form with improved stability
JP2010509363A (en) Process for the production of multi-phase pharmaceutical compositions in solid dosage forms
JP2006511536A5 (en)
TW201311236A (en) Celecoxib solid dispersion and its preparation method
JP6320371B2 (en) Pharmaceutical composition and production method of entecavir
JP2018502130A5 (en)
JP7269918B2 (en) Solid dosage form containing dutasteride and method for producing the same
EP3793530A1 (en) Solid dispersion containing ritonavir
JP2024012683A (en) High-strength oral taxane compositions and methods
US9662300B2 (en) Solid naproxen concentrates and related dosage forms
CA2966517C (en) Solid oral formulation of fenretinide
KR102290670B1 (en) Composition for oral solid preparation of rivaroxaban using self-nanoemulsifying drug delivery system and methods for their preparation
EP1753400A2 (en) Ziprasidone dosage form
EP2996679A1 (en) Tablet with increased drug load of odanacatib
EP1954256A2 (en) Pharmaceutical composition comprising a compound having a catechol moiety and an alkalising agent
EP2155168A2 (en) Stable pharmaceutical compositions of clopidogrel bisulfate and process of preparation thereof
WO2022180582A1 (en) Oral pharmaceutical composition of arsenic trioxide
JP2017513878A (en) Active ingredient (I) -containing composition and method for producing the same
TWI597063B (en) Pharmaceutical composition and preparation method thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20161220

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170728